Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR - Currency: USD

2.15  +0.01 (+0.47%)

After market: 2.02 -0.13 (-6.05%)

Fundamental Rating

2

Overall IPHA gets a fundamental rating of 2 out of 10. We evaluated IPHA against 558 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IPHA has reported negative net income.
IPHA had a negative operating cash flow in the past year.
In the past 5 years IPHA always reported negative net income.
IPHA had a negative operating cash flow in each of the past 5 years.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

The Return On Assets of IPHA (-44.54%) is comparable to the rest of the industry.
With a Return On Equity value of -560.01%, IPHA is not doing good in the industry: 78.85% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPHA has more shares outstanding than it did 1 year ago.
IPHA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IPHA has a worse debt to assets ratio.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IPHA has an Altman-Z score of -4.70. This is a bad value and indicates that IPHA is not financially healthy and even has some risk of bankruptcy.
IPHA has a Altman-Z score (-4.70) which is in line with its industry peers.
A Debt/Equity ratio of 8.02 is on the high side and indicates that IPHA has dependencies on debt financing.
IPHA has a Debt to Equity ratio of 8.02. This is amonst the worse of the industry: IPHA underperforms 84.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Altman-Z -4.7
ROIC/WACCN/A
WACC7.49%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.60 indicates that IPHA has no problem at all paying its short term obligations.
IPHA has a worse Current ratio (2.60) than 69.18% of its industry peers.
A Quick Ratio of 2.60 indicates that IPHA has no problem at all paying its short term obligations.
IPHA has a worse Quick ratio (2.60) than 67.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for IPHA have decreased strongly by -549.63% in the last year.
IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.68%.
The Revenue for IPHA have been decreasing by -28.80% on average. This is quite bad
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%

3.2 Future

Based on estimates for the next years, IPHA will show a very negative growth in Earnings Per Share. The EPS will decrease by -14.00% on average per year.
IPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.06% yearly.
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 24.08, the valuation of IPHA can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IPHA indicates a rather cheap valuation: IPHA is cheaper than 91.58% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IPHA to the average of the S&P500 Index (22.06), we can say IPHA is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 24.08
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

IPHA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IPHA's earnings are expected to decrease with -14.00% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.86%
EPS Next 3Y-14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (6/5/2025, 6:18:00 PM)

After market: 2.02 -0.13 (-6.05%)

2.15

+0.01 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)09-17 2025-09-17
Inst Owners9.86%
Inst Owner Change15.92%
Ins Owners2.39%
Ins Owner ChangeN/A
Market Cap198.14M
Analysts78.18
Price Target6.18 (187.44%)
Short Float %0.1%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.87%
PT rev (3m)17.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)161.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.08
P/S 13.79
P/FCF N/A
P/OCF N/A
P/B 19.7
P/tB 19.7
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.09
Fwd EY4.15%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.16
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.61%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -4.7
F-Score1
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
EPS Next Y121.73%
EPS Next 2Y75.86%
EPS Next 3Y-14%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%
Revenue Next Year86.96%
Revenue Next 2Y85.05%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%
EBIT growth 1Y-307.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.78%
EBIT Next 3Y30.44%
EBIT Next 5YN/A
FCF growth 1Y79.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.82%
OCF growth 3YN/A
OCF growth 5YN/A